posted
Grant Life Sciences To Exhibit At WealthExpo January 12-14 In Houston
Monday , January 09, 2006 00:07 ET
(financialwire.net via COMTEX) -- January 9, 2006 (FinancialWire) Grant Life Sciences (OTCBB: GLIF) will exhibit at the WealthExpo (http://www.worldforumexpo.com), an Investrend Forums (http://www.investrendforums.com) "SELECT" event, in Houston, Texas, on January 12-14 at the Westin Galleria Hotel.
Past participants have included Generex Biotech (NASDAQ: GNBT), and a presenter is expected to be Frank Holmes, CEO of US Global Investors (NASDAQ: GROW). Texas is home to several well-known public companies, such as Exxon Mobil (NYSE: XOM). Houston also boasts a high net worth investor base.
"Houston is the nation's fourth largest city," noted Mike Loebel, principal in Worldwide Forums of Scottsdale, the producer of the WealthExpos. "Its citizens deserve to be in the mainstream of investing opportunities on Wall Street and elsewhere, and that's exactly what WealthExpo delivers."
Those who register in advance may attend free; attendees otherwise will be charged $35 at the door. Workshops are scheduled in Energy, Commodities, Mutual Funds and Stock Trading. It also showcases new software, brokerage, advisory and research firms.
Speakers include Walter Bressert, John Person, Jake Bernstein and Robin Dain. Educators Vince Rowe and Dr. Barry Burns will also speak.
Stock experts Neil George and Elliot Gue will speak, and investing insight will be provided by Dan Gramza, Don Bright, Afshin Taghechian and Joe Cussisk.
The Houston event is scheduled 1 p.m. to 7 p.m. on Thursday, 8:30 a.m. to 5 p.m. on Friday and 8:30 a.m. to 4 p.m. on Saturday.
WealthExpos are also scheduled March 16-18 in Anaheim, May 4-6 in Atlanta, and September 7-9 in Dallas.
Public companies wanting information about exhibiting should click on http://www.investrend.com/contact.asp to be assure of all the special, enhanced visibility programs associated with becoming an Investrend "SELECT" participant in a "SELECT" event.
Grant Life Sciences, Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for detecting disease with emphasis on the detection of cervical disease. The company is developing two cervical cancer tests, Enzyme Linked Immunosorbent Assay Test (ELISA), to be run in a laboratory, and a rapid test to be a point-of-care test that would be administered in the hospital, physician's office, clinic, or at home or in outdoor settings. Its tests would detect the presence or absence of specific antibodies that are produced only if cancer-causing HPV is present in the body and consequent oncogenic or cancer-promoting changes occur. The company also holds worldwide rights to diagnostic devices for HIV-1, HIV-2, and dengue fever, and proprietary colloidal gold reagent, an ingredient used by manufacturers of rapid tests as a detectable label. Grant Life Sciences was organized in 1998 and is based in Murray, Utah.
Generex Biotech Corp. had enrolled in Investrend Research's unique and pioneering professional analyst program, which facilitates independent analysts to provide financial coverage for shareholders and investors in companies that otherwise would have little or no analyst following. Enrollment in standards-based research is an important measure of a company's commitment to transparency and Good Governance.
In a Focus Report initiated by Investrend Research analyst Shailesh Dhuri, the analyst stated on June 6, 2005, that the company "is working towards creating a potentially winning technology, with strong feature improvements over current options in the market."
The company's research is now stale.
The Investrend Research program is the largest in the world and includes a number of safeguards to reduce or eliminate conflict. These systems, including media coverage and endorsements, may be accessed at http://www.investrendresearch.com
Investrend Research subscribes to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adheres to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the CFA Institute (http://www.cfainstitute.org).
Buyside Magazine has stated that Investrend Research "remains in the vanguard of both standards and independence." ODwyerPR has cited Investrend Research as "exceeding the standards of CFAI-NIRI." The CFA Magazine, citing Investrend and its affiliates as having "strict rules about compensation and full disclosure," which "should go a long way towards ensuring objectivity," said "issuer-paid research is here to stay." Investrend has been cited by the Dow Jones Newswires, Financial Mail, Shareholder Value, and NIRI's "IR Update," which stated that Investrend "accomplishes the goal and more." Investrend's model has been endorsed by the New York Times, former SEC Chair Arthur Levitt and shareholders themselves, 70.9% of whom said in a survey at InvestoPedia, that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential." A survey at Charles Schwab & Co. revealed that 78% of active shareholders now "value research from independent firms over analysts by Wall Street firms with financial ties to the companies they are rating."
Enrollment fees for the Focus research platform are $9,950. The fees were paid by Investor Relations International.
All independent sponsored research distributed by Investrend Research Syndicate are enrolled for investor-monitoring by the Shareholders Research Alliance at http://www.shareholdersresearch.com.
Complete information about any company enrolled in an Investrend shareholder empowerment platform, including those of its affiliates and independent analysts and webcasters, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.
FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
